China discovers a flu drug reduces the chances of

infection with the (COVID-19)


China has completed clinical research on Favipiravir, an anti-viral drug that has demonstrated good clinical efficacy against the Corona Virus (COVID-19), a Chinese official said Tuesday.


Zhang Xinmin, director of the China National Center for Biotechnology Development of the Ministry of Science and Technology, said that faviravir, the influenza drug that was approved for secret use in Japan in 2014, showed no clear negative reactions in the clinical trial, but rather made its recipient less responsive to HIV opportunities. .

According to the Chinese agency, more than 80 patients participated in the clinical trial at the Third People’s Hospital in Shenzhen, south China’s Guangdong Province, including 35 patients who took faviravir and 45 patients in a control group. The results showed that patients treated with favirir treatment became passive to the virus in a shorter time compared to patients in the control group.


A randomized, multicenter clinical study conducted by Zhongnan Hospital at Wuhan University revealed that the therapeutic effect of Favipiravir was much better than that of the control group.

Zhang says that the China Medical Products Management Corporation has a Chinese pharmaceutical company to mass-produce the drug and ensure the supply stable.

Initial media reports stated that the drug “Favilavir” obtained the approval of the regulatory authorities as a drug for Corona virus, according to the website (, noting that the updated reports indicated that the company obtained approval to test the drug on patients «Covid-19 ».

The National Administration of Chinese Medical Products pointed out that the company met the requirements to manufacture the general version of the treatment, but it required more work in pharmacy research and clinical trials.

She added that “favelaver”, one of the three drugs that appear to be effective against coronavirus in human trials, has been approved, according to Zhang Xinmin, head of the China Biotechnology Center.

According to experiments, the drug had positive reactions and appeared encouragingly to patients with the Corona virus in trials conducted in Shenzhen, Guangdong Province.

In the context, the remaining two drugs that appear to be effective next to the favelavir treatment are chloroquine, an anti-malarial drug, where chloroquine, a current drug, is being evaluated, and is being tested on more than 100 patients in more than ten hospitals in Beijing and Guangdong Province, and an additional study is being planned in the county Hunan, meanwhile, chloroquine is said to be undergoing trials in more than 10 medical institutions in Wuhan, the epicentre of the outbreak of coronavirus.

A study conducted by the US National Institutes of Health (NIH) revealed that remicevir could prevent the Coronavirus from spreading and use the drug as an effective treatment for people with corona.

It is reported that earlier this month, the Wuhan Virus Institute submitted a new patent application for the remiferiver.